Gland Pharma announced that it has through its wholly owned subsidiary Gland Pharma International, Singapore entered into a Put Option Agreement to acquire 100% of Cenexi Group for an Equity Value not exceeding Euro 120 Mn (Enterprise Value of Euro 230 Mn). Founded in 2004, Cenexi, along with its Subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical […]
KPI Green Energy Limited has informed the Exchange about Board Meeting held on 30-Nov-2022 to consider Bonus and Other business matters. The Outcome is attached herewith.
Union Bank of India has allotted Unsecured, Subordinated, Non-Convertible, Taxable, Fully Paid-Up Basel III Compliant Tier- 2 Bonds in the nature of Debentures eligible for inclusion in Tier 2 Capital (Bonds) in two tranches of Rs.1500 crore (ISIN: INE692A08219,Series XXXVI-A) and Rs.700 crore (ISIN: INE692A08201,Series XXXVI-B) aggregating to Rs.2200 crore on 29 November 2022.Powered by Capital Market – Live News
Biocon Biologics, subsidiary of Biocon announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS). Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors. Effective from the date […]
In connection with the aforesaid delisting offer, this is to inform you that BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) have issued their final approval for the delisting of equity shares from both the Stock Exchanges, in compliance with regulation 25 and 26 of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 and pursuant to their letters dated November 28, 2022. Accordingly, the Acquirers have issued a public announcement with regard to the Delisting Exit Offer provided to remaining public shareholders of the Company dated November 29, 2022 and the same has been published today i.e November 30, 2022. Request you to take the same on your record.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
